Biofabrication

Redwire BioFabrication Facility Successfully Prints First Human Knee Meniscus on ISS, Paving the Way for Advanced In-Space Bioprinting Capabilities to Benefit Human Health

Retrieved on: 
Jeudi, septembre 7, 2023
Biotechnology, Other Manufacturing, General Health, Health, Health Technology, Aerospace, Manufacturing, Other Health, Luther Forest Technology Campus, Biofabrication, RDW, Redwire, Orbit, 3D bioprinting, Tear resistance, BFF, Uniformed Services University of the Health Sciences, Multimedia, Research, International Space Station, Regenerative medicine, Corporation, NASA, University of Texas Health Science Center at San Antonio, LEO, SpaceX, Injury, Meniscus, Scientific research on the International Space Station, Credit, NYSE, ISS, 3D printing, Communications satellite

This milestone opens the door to improved treatments for meniscal injuries, one of the most common injuries for U.S. Service Members.

Key Points: 
  • This milestone opens the door to improved treatments for meniscal injuries, one of the most common injuries for U.S. Service Members.
  • View the full release here: https://www.businesswire.com/news/home/20230907832309/en/
    Redwire’s 3D BioFabrication Facility successfully 3D printed the first human knee meniscus on the International Space Station, paving the way for advanced in-space bioprinting capabilities to benefit human health.
  • (Credit: Redwire)
    “This is a groundbreaking milestone with significant implications for human health,” said Redwire Executive Vice President John Vellinger.
  • Redwire has developed 20 research facilities for the ISS with 10 currently operating on station to deliver world-leading research.

Europe Lab-on-a-Chip and Microfluidics Conference 2023: Technology and Innovation in the Lab-on-a-Chip (LOAC) and Microfluidics Fields (Rotterdam, Netherlands - June 19-20, 2023) - ResearchAndMarkets.com

Retrieved on: 
Mercredi, avril 5, 2023
Other Science, Science, Exhibition, LSU Health Sciences Center Shreveport, Lab, Biofabrication, Global health, Research, Academy of Athens (modern), Printing, LOAC, TU Wien, Speaker, Point-of-care testing, Biophysics, Conference, Consumer electronics, 3D printing, Microfluidics

The "Lab-on-a-Chip and Microfluidics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lab-on-a-Chip and Microfluidics Europe 2023" conference has been added to ResearchAndMarkets.com's offering.
  • The Lab-on-a-Chip and Microfluidics Europe 2023 now in its 15th year brings together researchers and industry participants from both academia and industry focusing on technology and innovation in the Lab-on-a-Chip (LOAC) and Microfluidics fields.
  • Presentations will explore the latest advances in the Lab-on-a-Chip and Microfluidics Fields.
  • There is an Extensive International Perspective at this Conference with Speakers, Poster Presenters, Sponsors, and Exhibitors from Europe, US, and Asia/Pacific.

Bioprinting Markets and Opportunities Report 2022: Bioprinting Industry Revenues to Reach Almost $1.2 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Jeudi, décembre 29, 2022
Other Health, Medical Devices, Technology, Genetics, Science, Surgery, Biotechnology, Stem Cells, Medical Supplies, Other Technology, Other Science, Health, 3D bioprinting, Research, Patient, Printing, Biofabrication, D, R, 3D printing

Revenues from bioprinting are expected to reach almost $1.2 billion in 2028, compared with just $182 million today.

Key Points: 
  • Revenues from bioprinting are expected to reach almost $1.2 billion in 2028, compared with just $182 million today.
  • By 2028, the analyst expects almost 70 percent of the bioprinting industry to come from applications and service revenues.
  • The new report, "Bioprinting: Markets and Opportunities", claims that we are many years from transplanting printed organs.
  • By 2031 the analyst expects production grade bioprinters or biomanufacturing platforms incorporating bioprinting to clock up around $100 million in revenues.

Global Bioprinting Markets and Opportunities Report 2022: How the Major Bioprinting Companies are Designing their Marketing Strategies to Take their Share of the $1.2 Billion Industry

Retrieved on: 
Mercredi, janvier 4, 2023
Desktop Metal, Metal, Drug discovery, 3D, Therapy, 3D bioprinting, Biofabrication, R, Research, Patient, D, Hospital, Cellink, Printing, Pharmaceutical industry, 3D printing

In addition to the pure play bioprinting companies, the bioprinting sector is seeing involvement from major life science companies and 3D printing companies.

Key Points: 
  • In addition to the pure play bioprinting companies, the bioprinting sector is seeing involvement from major life science companies and 3D printing companies.
  • By 2028, the analyst expects almost 70 percent of the bioprinting industry to come from applications and service revenues.
  • The analyst has been tracking the bioprinting industry for almost a decade and this is its third major bioprinting report.
  • By 2031 the analyst expects production grade bioprinters or biomanufacturing platforms incorporating bioprinting to clock up around $100 million in revenues.

NASA Science, Cargo Launches on Northrop Grumman Resupply Mission

Retrieved on: 
Lundi, novembre 7, 2022
DNA, Research, NASA TV, Science, Biofabrication, Wallops Flight Facility, Student, Multimedia, Biotechnology, Modulation, Biology, Theca, Human, NASA, Sand, Moon, Fertility, Television, Antares (rocket), Spacecraft, Wildfire, Printing, Food, ASI, Plant, Transplant, Northrop, Exploration, Grumman, Gene, EST, Patient, Artemis, Unity, Commercial Resupply Services, Water, Communications satellite, 3D printing, Cygnus, Mars, Wallop (disambiguation)

NASA Television, the NASA app , and the agency's websitewill provide live coverage of the spacecraft's approach beginning at 3:30 a.m. Wednesday, Nov. 9.

Key Points: 
  • NASA Television, the NASA app , and the agency's websitewill provide live coverage of the spacecraft's approach beginning at 3:30 a.m. Wednesday, Nov. 9.
  • Northrop Grumman's 18th cargo flight to the space station is the seventh under its Commercial Resupply Services 2 contract with NASA.
  • The resupply mission will support dozens of the more than 250 investigations that will be conducted during Expedition 68.
  • Learn more about Northrop Grumman's mission at:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/nasa-science-cargo-launches-on-...

CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy

Retrieved on: 
Lundi, septembre 19, 2022
3D Systems, 3D, Bio-ink, Genetic engineering, Company, Regeneration, Technology, 3D bioprinting, Tissue, NASDAQ, Conference, AbbVie, International Conference on Applied Human Factors and Ergonomics, Allergan, Biofabrication, Medical imaging

CollPlant will also have an exhibition booth at the Conference from Sept 25th-28th.

Key Points: 
  • CollPlant will also have an exhibition booth at the Conference from Sept 25th-28th.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.
  • The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology.
  • Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

CollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada

Retrieved on: 
Mardi, juillet 5, 2022
Biofabrication, 3D Systems, TERMIS, Tissue, Genetic engineering, Regenerative medicine, Form 20-F, Ideal, Tissue Engineering and Regenerative Medicine International Society, 3D, COVID-19, Tissue engineering, Marketing, Public expenditure, Company, Industry, Intellectual property, Allergan, AbbVie, 3D bioprinting, Annual report, Terminology, Regeneration, Perception, Exhibition, Clinical trial, Technology, SEC, Risk, NASDAQ, Bio-ink, Forward-looking statement, Medical imaging, Pharmaceutical industry

REHOVOT, Israel, July 5, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the company will deliver two presentations, and will have an exhibition booth at the annual conference and exhibition of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), in Toronto, Canada, on July 10-13, 2022.

Key Points: 
  • "We look forward to participating at the TERMIS conference, a leading organization in the field of tissue engineering and regenerative medicine," said Yehiel Tal, CollPlant's Chief Executive Officer.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.
  • The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology.
  • For more information about CollPlant, visit http://www.collplant.com
    This press release may include forward-looking statements.

CollPlant CEO Yehiel Tal to Moderate ISBF's virtual event on Biofabrication of Microphysiological Systems for Drug Discovery and Screening

Retrieved on: 
Lundi, avril 25, 2022
Annual report, Public expenditure, CTO, Genetic engineering, Clinical trial, 3D bioprinting, Marketing, COVID-19, Cell biology, VP, Research, Boston University, Allergan, AbbVie, Terminology, Risk, Regenerative medicine, Tissue, Q&A, Intellectual property, Conference, CSO, Technology, Company, Society, Industry, SEC, 3D, International Society, Forward-looking statement, Bio-ink, 3D Systems, Tokyo International Conference on African Development, Form 20-F, Regeneration, Perception, Pharmaceutical industry, Online shopping, Medical imaging, Biofabrication, Tel Aviv University

The Q&A session will be moderated by Ms. Katie Weimer, VP Regenerative Medicine at 3D systems and a member of the ISBF's Industry Relations Committee.

Key Points: 
  • The Q&A session will be moderated by Ms. Katie Weimer, VP Regenerative Medicine at 3D systems and a member of the ISBF's Industry Relations Committee.
  • For more details and to register, please visit https://biofabricationsociety.org/
    From basic science to medical applications, the biofabrication community convened at the International Conference on Biofabrication (Biofabrication 2019).
  • The field of biofabrication is dedicated to researching and integrating technologies such as bio-printing, bio-plotting, and bio-assembly into applications such as engineered tissue systems and regenerative medicine.
  • CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics.

Europe Biofabrication & Biomanufacturing Conference 2019: Focus on Advanced Techniques and Approaches - Rotterdam, Netherlands - June 20th-21st, 2019

Retrieved on: 
Mercredi, février 20, 2019
3D printing processes, Natural sciences, Physical sciences, Academic journals, Biofabrication, Tissue engineering, Stereolithography, Photopolymer

DUBLIN, Feb. 20, 2019 /PRNewswire/ -- The "Biofabrication & Biomanufacturing Europe 2019" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 20, 2019 /PRNewswire/ -- The "Biofabrication & Biomanufacturing Europe 2019" conference has been added to ResearchAndMarkets.com's offering.
  • Biofabrication and Biomanufacturing Europe 2019 brings together researchers from across various disciplines who are involved in the fabrication of functional, engineered tissue constructs.
  • A multitude of fabrication approaches to generate tissue engineered constructs exist including photopolymerization, 3D-printing, stereolithography, multiphoton lithography as well as self-assembly approaches.
  • This conference will focus on advanced techniques and approaches being used for biofabrication with a focus on potentially scalable technologies that will allow higher throughput manufacturing of functional tissues.

2-Day Conference: Biofabrication & Biomanufacturing Europe, 2019 (Rotterdam, Netherlands - June 20-21, 2019) - ResearchAndMarkets.com

Retrieved on: 
Jeudi, février 14, 2019
Health, Biotechnology, Visual arts, Industrial processes, Printing, 3D printing processes, Adhesives, Photochemistry, Photopolymer, Polymers, Stereolithography, Biofabrication, Tissue engineering, Lithography

The "Biofabrication & Biomanufacturing Europe 2019" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biofabrication & Biomanufacturing Europe 2019" conference has been added to ResearchAndMarkets.com's offering.
  • Biofabrication and Biomanufacturing Europe 2019 brings together researchers from across various disciplines who are involved in the fabrication of functional, engineered tissue constructs.
  • A multitude of fabrication approaches to generate tissue engineered constructs exist including photopolymerization, 3D-printing, stereolithography, multiphoton lithography as well as self-assembly approaches.
  • In addition to scientific presentations, this conference features exhibits with companies showcasing their technologies and product offerings into this field.